Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN4A | P35499 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692056 | 0.72 | LMNA (0.33) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL4620116 | 0.68 | LMNA (0.31) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL4558728 | 0.67 | LMNA (0.38) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL22069 | 0.67 | — | — | |
| SCHEMBL6695121 | 0.65 | LMNA (0.43) | LMNAALDH1A1MMP2MMP9 | |
| SCHEMBL6694074 | 0.65 | — | — | |
| SCHEMBL12803697 | 0.65 | LMNA (0.36) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL6278824 | 0.65 | LMNA (0.36) | LMNACACNA1FALDH1A1MAPTCYP2C9 | |
| SCHEMBL21196916 | 0.65 | — | — | |
| SCHEMBL6162987 | 0.65 | LMNA (0.36) | LMNACACNA1FALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20040200780-A1 | Methods and systems for uniform control of bromine concentrations in water | HOWARTH JONATHAN N (US) | 2004-10-14 | — | — | US | disclosed |
| US-6749758-B2 | Methods and systems for uniform-control of bromine concentrations in water | ALBEMARLE CORPORATION | 2004-06-15 | — | — | US | disclosed |
| WO-2003047345-A2 | METHOD FOR UNIFORM CONTROL OF BROMINE CONCENTRATIONS IN BIOCIDAL WATER | ALBEMARLE CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030102271-A1 | Methods and systems for uniform control of bromine concentrations in water | ALBEMARLE CORPORATION | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858344-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | LMNA 1856/4885CACNA1F 4531/4885ALDH1A1 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.